These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24840260)

  • 1. Strategies for treating lipids for prevention: risk stratification models with and without imaging.
    Okwuosa TM; Mallikethi-Reddy S; Jones DM
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):295-307. PubMed ID: 24840260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do novel biomarkers add to existing scores of total cardiovascular risk?
    De Backer G; Graham I; Cooney MT
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):14-7. PubMed ID: 22801065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring clinical predictors of cardiovascular disease in a central Australian Aboriginal cohort.
    Luke JN; Brown AD; Brazionis L; O'Dea K; Best JD; McDermott RA; Wang Z; Wang Z; Rowley KG
    Eur J Prev Cardiol; 2013 Apr; 20(2):246-53. PubMed ID: 22345691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of different point-of-care testing lipid analysers on cardiovascular disease risk assessment.
    Whitehead SJ; Ford C; Gama R
    J Clin Pathol; 2014 Jun; 67(6):535-9. PubMed ID: 24711512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric lipidology.
    Moodie D
    Congenit Heart Dis; 2013; 8(4):271-2. PubMed ID: 23875778
    [No Abstract]   [Full Text] [Related]  

  • 7. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 8. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA₂) and lipoprotein(a) (Lp(a)).
    Dallmeier D; Koenig W
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):281-94. PubMed ID: 24840259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
    Zannad F; De Backer G; Graham I; Lorenz M; Mancia G; Morrow DA; Reiner Z; Koenig W; Dallongeville J; Macfadyen RJ; Ruilope LM; Wilhelmsen L;
    Fundam Clin Pharmacol; 2012 Apr; 26(2):163-74. PubMed ID: 22220636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for lipid disorders.
    Bell DA; Hooper AJ; Bender R; Edwards G; van Bockxmeer FM; Watts GF; Burnett JR
    Pathology; 2012 Feb; 44(2):115-21. PubMed ID: 22198257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease.
    Petersson U; Ostgren CJ; Brudin L; Nilsson PM
    Eur J Cardiovasc Prev Rehabil; 2009 Oct; 16(5):536-40. PubMed ID: 19357517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting levels and functions of blood lipids in the prevention of CVD.
    Mearns BM
    Nat Rev Cardiol; 2011 Apr; 8(4):179-80. PubMed ID: 21436841
    [No Abstract]   [Full Text] [Related]  

  • 13. A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality.
    Støvring H; Harmsen CG; Wisløff T; Jarbøl DE; Nexøe J; Nielsen JB; Kristiansen IS
    Eur J Prev Cardiol; 2013 Oct; 20(5):827-36. PubMed ID: 22498473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia therapy update: the importance of full lipid profile assessment.
    Menown IB; Murtagh G; Maher V; Cooney MT; Graham IM; Tomkin G
    Adv Ther; 2009 Jul; 26(7):711-8. PubMed ID: 19649582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms.
    Zomer E; Liew D; Owen A; Magliano DJ; Ademi Z; Reid CM
    Eur J Prev Cardiol; 2014 Mar; 21(3):384-90. PubMed ID: 22588087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: a global perspective.
    Mendis S
    Prog Cardiovasc Dis; 2010; 53(1):10-4. PubMed ID: 20620420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dislypidemia as a risk factor for cardiovascular disease].
    Anghel L; Ghiuru R; Gavrilescu CM
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):977-81. PubMed ID: 21500446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The systematic coronary risk evaluation (SCORE) for the prevention of cardiovascular diseases. Does evidence exist for its effectiveness? A systematic review.
    Tomasik T; Krzysztoń J; Dubas-Jakóbczyk K; Kijowska V; Windak A
    Acta Cardiol; 2017 Aug; 72(4):370-379. PubMed ID: 28705107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between serum lipids and causes of mortality in a cohort of 3,499 urban Thais: The Electricity Generating Authority of Thailand (EGAT) study.
    Sritara P; Patoomanunt P; Woodward M; Narksawat K; Tulyadachanon S; Ratanachaiwong W; Sritara C; Barzi F; Yamwong S; Tanomsup S
    Angiology; 2007 Dec-2008 Jan; 58(6):757-63. PubMed ID: 18216384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid profile parameters in Malaysian dyslipidemic patients.
    Al-Khateeb A; Mohamed MS; Imran K; Ibrahim S; Zilfalil BA; Yusof Z
    Kobe J Med Sci; 2011 Dec; 57(2):E38-48. PubMed ID: 22926072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.